Revisiting immune escape in colorectal cancer in the era of immunotherapy
In colorectal cancer (CRC), T-cell checkpoint blockade is only effective in patients diagnosed with mismatch repair-deficient (MMR-d) cancers. However, defects in Human Leukocyte Antigen (HLA) class I expression were reported to occur in most MMR-d CRCs, which would preclude antigen presentation in...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2019-04, Vol.120 (8), p.815-818 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 818 |
|---|---|
| container_issue | 8 |
| container_start_page | 815 |
| container_title | British journal of cancer |
| container_volume | 120 |
| creator | Ijsselsteijn, Marieke Erica Petitprez, Florent Lacroix, Laetitia Ruano, Dina van der Breggen, Ruud Julie, Catherine Morreau, Hans Sautès-Fridman, Catherine Fridman, Wolf Herman de Miranda, Noel Filipe da Cunha Carvalho |
| description | In colorectal cancer (CRC), T-cell checkpoint blockade is only effective in patients diagnosed with mismatch repair-deficient (MMR-d) cancers. However, defects in Human Leukocyte Antigen (HLA) class I expression were reported to occur in most MMR-d CRCs, which would preclude antigen presentation in these tumours, considered essential for the clinical activity of this immunotherapeutic modality. We revisited this paradox by characterising HLA class I expression in two independent cohorts of CRC. We determined that loss of HLA class I expression occurred in the majority (73–78%) of MMR-d cases. This phenotype was rare in CRC liver metastases, irrespective of MMR status, whereas weak, inducible expression of HLA class I molecules was frequent in liver lesions. We propose that HLA class I is an important determinant of metastatic homing in CRCs. This observation is paramount to understand CRC carcinogenesis and for the application of immunotherapies in the metastatic setting. |
| doi_str_mv | 10.1038/s41416-019-0421-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6474276</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2210425420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-26d0d26fee14e978a37c2616bd5eea50b10b7e13770ebf27baf0974eb831993b3</originalsourceid><addsrcrecordid>eNp1kU1LAzEQhoMotlZ_gBdZ8ORhdSab3exeBCl-FAqC6Dlk09l2pd3UZFvsvzdltX6Ap5CZ532HmZexU4RLhCS_8gIFZjFgEYPgGL_vsT6mCY8x53Kf9QFAxlBw6LEj71_Dt4BcHrJeAnnGixT7bPRE69rXbd1Mo3qxWDUUkTd6SVHdRMbOrSPT6nlkdGPIbYvtLCBOR7bqBDYUnF5ujtlBpeeeTj7fAXu5u30ePsTjx_vR8GYcmxREG_NsAhOeVUQoqJC5TqThGWblJCXSKZQIpSRMpAQqKy5LXUEhBZV5gkWRlMmAXXe-y1W5oImhpnV6rpauXmi3UVbX6nenqWdqatcqE1JwmQWDi85g9kf2cDNW2xpw5JBjusbAnn8Oc_ZtRb5Vr3blmrCf4hzD0VPBIVDYUcZZ7x1VO1sEtU1KdUmpkJTaJqXeg-bs5xo7xVc0AeAd4EOrmZL7Hv2_6werkp8K</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2210425420</pqid></control><display><type>article</type><title>Revisiting immune escape in colorectal cancer in the era of immunotherapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Ijsselsteijn, Marieke Erica ; Petitprez, Florent ; Lacroix, Laetitia ; Ruano, Dina ; van der Breggen, Ruud ; Julie, Catherine ; Morreau, Hans ; Sautès-Fridman, Catherine ; Fridman, Wolf Herman ; de Miranda, Noel Filipe da Cunha Carvalho</creator><creatorcontrib>Ijsselsteijn, Marieke Erica ; Petitprez, Florent ; Lacroix, Laetitia ; Ruano, Dina ; van der Breggen, Ruud ; Julie, Catherine ; Morreau, Hans ; Sautès-Fridman, Catherine ; Fridman, Wolf Herman ; de Miranda, Noel Filipe da Cunha Carvalho</creatorcontrib><description>In colorectal cancer (CRC), T-cell checkpoint blockade is only effective in patients diagnosed with mismatch repair-deficient (MMR-d) cancers. However, defects in Human Leukocyte Antigen (HLA) class I expression were reported to occur in most MMR-d CRCs, which would preclude antigen presentation in these tumours, considered essential for the clinical activity of this immunotherapeutic modality. We revisited this paradox by characterising HLA class I expression in two independent cohorts of CRC. We determined that loss of HLA class I expression occurred in the majority (73–78%) of MMR-d cases. This phenotype was rare in CRC liver metastases, irrespective of MMR status, whereas weak, inducible expression of HLA class I molecules was frequent in liver lesions. We propose that HLA class I is an important determinant of metastatic homing in CRCs. This observation is paramount to understand CRC carcinogenesis and for the application of immunotherapies in the metastatic setting.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-019-0421-x</identifier><identifier>PMID: 30862951</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/2161 ; 692/4028/67/1504/1885 ; 692/4028/67/322 ; 692/4028/67/580/1884/2323 ; 692/420/755 ; Antigen presentation ; Antigen Presentation - immunology ; Antigenic determinants ; Antigens ; Biomedical and Life Sciences ; Biomedicine ; Brain Neoplasms - genetics ; Brain Neoplasms - immunology ; Brief Communication ; Cancer ; Cancer Research ; Carcinogenesis ; Carcinogenesis - genetics ; Carcinogenesis - immunology ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - immunology ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - therapy ; Drug Resistance ; Epidemiology ; Female ; Gene Expression Regulation, Neoplastic - immunology ; Genes, cdc - drug effects ; Genes, cdc - immunology ; Genes, MHC Class I - genetics ; Homing ; Human health and pathology ; Humans ; Hépatology and Gastroenterology ; Immune checkpoint ; Immune evasion ; Immunology ; Immunotherapy ; Lesions ; Life Sciences ; Liver ; Liver - metabolism ; Liver - pathology ; Lymphocytes T ; Male ; Metastases ; Metastasis ; Middle Aged ; Mismatch repair ; Molecular Medicine ; Neoplasm Metastasis ; Neoplastic Syndromes, Hereditary - genetics ; Neoplastic Syndromes, Hereditary - immunology ; Oncology ; Phenotypes ; T-Lymphocytes - immunology ; Tumors</subject><ispartof>British journal of cancer, 2019-04, Vol.120 (8), p.815-818</ispartof><rights>The Author(s) 2019</rights><rights>This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-26d0d26fee14e978a37c2616bd5eea50b10b7e13770ebf27baf0974eb831993b3</citedby><cites>FETCH-LOGICAL-c504t-26d0d26fee14e978a37c2616bd5eea50b10b7e13770ebf27baf0974eb831993b3</cites><orcidid>0000-0003-1735-8722</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474276/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474276/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,41469,42538,51300,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30862951$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.sorbonne-universite.fr/hal-02120815$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Ijsselsteijn, Marieke Erica</creatorcontrib><creatorcontrib>Petitprez, Florent</creatorcontrib><creatorcontrib>Lacroix, Laetitia</creatorcontrib><creatorcontrib>Ruano, Dina</creatorcontrib><creatorcontrib>van der Breggen, Ruud</creatorcontrib><creatorcontrib>Julie, Catherine</creatorcontrib><creatorcontrib>Morreau, Hans</creatorcontrib><creatorcontrib>Sautès-Fridman, Catherine</creatorcontrib><creatorcontrib>Fridman, Wolf Herman</creatorcontrib><creatorcontrib>de Miranda, Noel Filipe da Cunha Carvalho</creatorcontrib><title>Revisiting immune escape in colorectal cancer in the era of immunotherapy</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>In colorectal cancer (CRC), T-cell checkpoint blockade is only effective in patients diagnosed with mismatch repair-deficient (MMR-d) cancers. However, defects in Human Leukocyte Antigen (HLA) class I expression were reported to occur in most MMR-d CRCs, which would preclude antigen presentation in these tumours, considered essential for the clinical activity of this immunotherapeutic modality. We revisited this paradox by characterising HLA class I expression in two independent cohorts of CRC. We determined that loss of HLA class I expression occurred in the majority (73–78%) of MMR-d cases. This phenotype was rare in CRC liver metastases, irrespective of MMR status, whereas weak, inducible expression of HLA class I molecules was frequent in liver lesions. We propose that HLA class I is an important determinant of metastatic homing in CRCs. This observation is paramount to understand CRC carcinogenesis and for the application of immunotherapies in the metastatic setting.</description><subject>631/250/2161</subject><subject>692/4028/67/1504/1885</subject><subject>692/4028/67/322</subject><subject>692/4028/67/580/1884/2323</subject><subject>692/420/755</subject><subject>Antigen presentation</subject><subject>Antigen Presentation - immunology</subject><subject>Antigenic determinants</subject><subject>Antigens</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - immunology</subject><subject>Brief Communication</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Carcinogenesis</subject><subject>Carcinogenesis - genetics</subject><subject>Carcinogenesis - immunology</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - immunology</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Colorectal Neoplasms - therapy</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic - immunology</subject><subject>Genes, cdc - drug effects</subject><subject>Genes, cdc - immunology</subject><subject>Genes, MHC Class I - genetics</subject><subject>Homing</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Hépatology and Gastroenterology</subject><subject>Immune checkpoint</subject><subject>Immune evasion</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Lesions</subject><subject>Life Sciences</subject><subject>Liver</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Mismatch repair</subject><subject>Molecular Medicine</subject><subject>Neoplasm Metastasis</subject><subject>Neoplastic Syndromes, Hereditary - genetics</subject><subject>Neoplastic Syndromes, Hereditary - immunology</subject><subject>Oncology</subject><subject>Phenotypes</subject><subject>T-Lymphocytes - immunology</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kU1LAzEQhoMotlZ_gBdZ8ORhdSab3exeBCl-FAqC6Dlk09l2pd3UZFvsvzdltX6Ap5CZ532HmZexU4RLhCS_8gIFZjFgEYPgGL_vsT6mCY8x53Kf9QFAxlBw6LEj71_Dt4BcHrJeAnnGixT7bPRE69rXbd1Mo3qxWDUUkTd6SVHdRMbOrSPT6nlkdGPIbYvtLCBOR7bqBDYUnF5ujtlBpeeeTj7fAXu5u30ePsTjx_vR8GYcmxREG_NsAhOeVUQoqJC5TqThGWblJCXSKZQIpSRMpAQqKy5LXUEhBZV5gkWRlMmAXXe-y1W5oImhpnV6rpauXmi3UVbX6nenqWdqatcqE1JwmQWDi85g9kf2cDNW2xpw5JBjusbAnn8Oc_ZtRb5Vr3blmrCf4hzD0VPBIVDYUcZZ7x1VO1sEtU1KdUmpkJTaJqXeg-bs5xo7xVc0AeAd4EOrmZL7Hv2_6werkp8K</recordid><startdate>20190416</startdate><enddate>20190416</enddate><creator>Ijsselsteijn, Marieke Erica</creator><creator>Petitprez, Florent</creator><creator>Lacroix, Laetitia</creator><creator>Ruano, Dina</creator><creator>van der Breggen, Ruud</creator><creator>Julie, Catherine</creator><creator>Morreau, Hans</creator><creator>Sautès-Fridman, Catherine</creator><creator>Fridman, Wolf Herman</creator><creator>de Miranda, Noel Filipe da Cunha Carvalho</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Cancer Research UK</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1735-8722</orcidid></search><sort><creationdate>20190416</creationdate><title>Revisiting immune escape in colorectal cancer in the era of immunotherapy</title><author>Ijsselsteijn, Marieke Erica ; Petitprez, Florent ; Lacroix, Laetitia ; Ruano, Dina ; van der Breggen, Ruud ; Julie, Catherine ; Morreau, Hans ; Sautès-Fridman, Catherine ; Fridman, Wolf Herman ; de Miranda, Noel Filipe da Cunha Carvalho</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-26d0d26fee14e978a37c2616bd5eea50b10b7e13770ebf27baf0974eb831993b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>631/250/2161</topic><topic>692/4028/67/1504/1885</topic><topic>692/4028/67/322</topic><topic>692/4028/67/580/1884/2323</topic><topic>692/420/755</topic><topic>Antigen presentation</topic><topic>Antigen Presentation - immunology</topic><topic>Antigenic determinants</topic><topic>Antigens</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - immunology</topic><topic>Brief Communication</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Carcinogenesis</topic><topic>Carcinogenesis - genetics</topic><topic>Carcinogenesis - immunology</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - immunology</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Colorectal Neoplasms - therapy</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic - immunology</topic><topic>Genes, cdc - drug effects</topic><topic>Genes, cdc - immunology</topic><topic>Genes, MHC Class I - genetics</topic><topic>Homing</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Hépatology and Gastroenterology</topic><topic>Immune checkpoint</topic><topic>Immune evasion</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Lesions</topic><topic>Life Sciences</topic><topic>Liver</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Mismatch repair</topic><topic>Molecular Medicine</topic><topic>Neoplasm Metastasis</topic><topic>Neoplastic Syndromes, Hereditary - genetics</topic><topic>Neoplastic Syndromes, Hereditary - immunology</topic><topic>Oncology</topic><topic>Phenotypes</topic><topic>T-Lymphocytes - immunology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ijsselsteijn, Marieke Erica</creatorcontrib><creatorcontrib>Petitprez, Florent</creatorcontrib><creatorcontrib>Lacroix, Laetitia</creatorcontrib><creatorcontrib>Ruano, Dina</creatorcontrib><creatorcontrib>van der Breggen, Ruud</creatorcontrib><creatorcontrib>Julie, Catherine</creatorcontrib><creatorcontrib>Morreau, Hans</creatorcontrib><creatorcontrib>Sautès-Fridman, Catherine</creatorcontrib><creatorcontrib>Fridman, Wolf Herman</creatorcontrib><creatorcontrib>de Miranda, Noel Filipe da Cunha Carvalho</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ijsselsteijn, Marieke Erica</au><au>Petitprez, Florent</au><au>Lacroix, Laetitia</au><au>Ruano, Dina</au><au>van der Breggen, Ruud</au><au>Julie, Catherine</au><au>Morreau, Hans</au><au>Sautès-Fridman, Catherine</au><au>Fridman, Wolf Herman</au><au>de Miranda, Noel Filipe da Cunha Carvalho</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Revisiting immune escape in colorectal cancer in the era of immunotherapy</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2019-04-16</date><risdate>2019</risdate><volume>120</volume><issue>8</issue><spage>815</spage><epage>818</epage><pages>815-818</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>In colorectal cancer (CRC), T-cell checkpoint blockade is only effective in patients diagnosed with mismatch repair-deficient (MMR-d) cancers. However, defects in Human Leukocyte Antigen (HLA) class I expression were reported to occur in most MMR-d CRCs, which would preclude antigen presentation in these tumours, considered essential for the clinical activity of this immunotherapeutic modality. We revisited this paradox by characterising HLA class I expression in two independent cohorts of CRC. We determined that loss of HLA class I expression occurred in the majority (73–78%) of MMR-d cases. This phenotype was rare in CRC liver metastases, irrespective of MMR status, whereas weak, inducible expression of HLA class I molecules was frequent in liver lesions. We propose that HLA class I is an important determinant of metastatic homing in CRCs. This observation is paramount to understand CRC carcinogenesis and for the application of immunotherapies in the metastatic setting.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30862951</pmid><doi>10.1038/s41416-019-0421-x</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-1735-8722</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2019-04, Vol.120 (8), p.815-818 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6474276 |
| source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | 631/250/2161 692/4028/67/1504/1885 692/4028/67/322 692/4028/67/580/1884/2323 692/420/755 Antigen presentation Antigen Presentation - immunology Antigenic determinants Antigens Biomedical and Life Sciences Biomedicine Brain Neoplasms - genetics Brain Neoplasms - immunology Brief Communication Cancer Cancer Research Carcinogenesis Carcinogenesis - genetics Carcinogenesis - immunology Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - genetics Colorectal Neoplasms - immunology Colorectal Neoplasms - pathology Colorectal Neoplasms - therapy Drug Resistance Epidemiology Female Gene Expression Regulation, Neoplastic - immunology Genes, cdc - drug effects Genes, cdc - immunology Genes, MHC Class I - genetics Homing Human health and pathology Humans Hépatology and Gastroenterology Immune checkpoint Immune evasion Immunology Immunotherapy Lesions Life Sciences Liver Liver - metabolism Liver - pathology Lymphocytes T Male Metastases Metastasis Middle Aged Mismatch repair Molecular Medicine Neoplasm Metastasis Neoplastic Syndromes, Hereditary - genetics Neoplastic Syndromes, Hereditary - immunology Oncology Phenotypes T-Lymphocytes - immunology Tumors |
| title | Revisiting immune escape in colorectal cancer in the era of immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T06%3A42%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Revisiting%20immune%20escape%20in%20colorectal%20cancer%20in%20the%20era%20of%20immunotherapy&rft.jtitle=British%20journal%20of%20cancer&rft.au=Ijsselsteijn,%20Marieke%20Erica&rft.date=2019-04-16&rft.volume=120&rft.issue=8&rft.spage=815&rft.epage=818&rft.pages=815-818&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-019-0421-x&rft_dat=%3Cproquest_pubme%3E2210425420%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2210425420&rft_id=info:pmid/30862951&rfr_iscdi=true |